HK1056514A1 - Use of kcnq potassium channel agonists for the manufacture of a medicament for modulating bladder function - Google Patents

Use of kcnq potassium channel agonists for the manufacture of a medicament for modulating bladder function

Info

Publication number
HK1056514A1
HK1056514A1 HK03108976A HK03108976A HK1056514A1 HK 1056514 A1 HK1056514 A1 HK 1056514A1 HK 03108976 A HK03108976 A HK 03108976A HK 03108976 A HK03108976 A HK 03108976A HK 1056514 A1 HK1056514 A1 HK 1056514A1
Authority
HK
Hong Kong
Prior art keywords
medicament
manufacture
potassium channel
bladder function
channel agonists
Prior art date
Application number
HK03108976A
Other languages
English (en)
Inventor
Thomas Michael Argentieri
Jeffrey Howard Sheldon
Mark Robert Bowlby
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1056514(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of HK1056514A1 publication Critical patent/HK1056514A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/341—Urinary incontinence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03108976A 2000-10-17 2003-12-10 Use of kcnq potassium channel agonists for the manufacture of a medicament for modulating bladder function HK1056514A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24107800P 2000-10-17 2000-10-17
US28142801P 2001-04-04 2001-04-04
PCT/US2001/032204 WO2002032419A2 (en) 2000-10-17 2001-10-16 Methods for modulating bladder function

Publications (1)

Publication Number Publication Date
HK1056514A1 true HK1056514A1 (en) 2004-02-20

Family

ID=26933980

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03108976A HK1056514A1 (en) 2000-10-17 2003-12-10 Use of kcnq potassium channel agonists for the manufacture of a medicament for modulating bladder function

Country Status (23)

Country Link
US (3) US6348486B1 (no)
EP (2) EP1326597B1 (no)
JP (2) JP2004511516A (no)
KR (1) KR20030040540A (no)
CN (1) CN1287781C (no)
AR (1) AR030901A1 (no)
AT (1) ATE314061T1 (no)
AU (2) AU2002211758A1 (no)
BR (1) BR0114718A (no)
CA (2) CA2450467C (no)
CY (1) CY1105353T1 (no)
DE (1) DE60116352T2 (no)
DK (1) DK1326597T3 (no)
ES (1) ES2253432T3 (no)
HK (1) HK1056514A1 (no)
HU (1) HUP0303288A2 (no)
IL (1) IL155090A0 (no)
MX (1) MXPA03003339A (no)
NO (1) NO20031580L (no)
NZ (1) NZ525301A (no)
PL (1) PL360903A1 (no)
TW (1) TWI287984B (no)
WO (2) WO2002032419A2 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
WO2002080898A2 (en) * 2001-04-04 2002-10-17 Wyeth Methods for treating hyperactive gastric motility
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
EP1553932A2 (en) * 2002-10-21 2005-07-20 Ramot at Tel Aviv University Ltd. Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
WO2004096767A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
WO2004099442A2 (en) * 2003-05-06 2004-11-18 University Hospital Of Basel Kcnma1 as a therapeutic target in cancer treatment
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
PT1530967E (pt) * 2003-11-13 2006-09-29 Ferring Bv Embalagem blister e uma forma de dosagem solida que compreende desmopressina.
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
WO2007084497A1 (en) * 2006-01-19 2007-07-26 Wyeth A novel rat voltage-gated potassium channel
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
EP2061465B1 (en) * 2006-08-23 2013-04-10 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8030518B2 (en) * 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
DE102007012029A1 (de) 2007-03-13 2008-09-18 Grünenthal GmbH Verfahren zur Identifizierung der agonistischen Aktivität einer Zielverbindung auf einen Kaliumkanal
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US8399410B2 (en) 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2009037707A2 (en) * 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
DK3085381T3 (en) * 2008-05-21 2018-05-28 Ferring Bv ORODISPERSIBLE DESMOPRESSIN TO INCREASE THE INITIAL PERIOD OF SLEEP UNDERSTANDED BY NEW TURRY
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
CN102170879B (zh) * 2008-07-18 2014-03-05 威朗国际制药公司 调控释放制剂及其应用方法
WO2011101456A2 (en) * 2010-02-19 2011-08-25 Medichem S.A. Stabilized phenylcarbamate derivative in solid state
WO2013165575A1 (en) * 2012-04-30 2013-11-07 Scifluor Life Sciences, Llc Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US11358930B2 (en) 2018-04-20 2022-06-14 University of Pittsburgh—of the Commonwealth System of Higher Education Selective potassium channel agonists
EP3912625A1 (en) 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37460A (en) * 1863-01-20 Improvement in meat-broilers
GB9220570D0 (en) * 1991-10-21 1992-11-11 Ici Plc Therapeutic agent
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
US6277978B1 (en) * 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
DE69837267T2 (de) * 1997-08-12 2007-10-31 Bristol-Myers Squibb Co. Kcnq kaliumkanäle und verfahren zur deren modulierung
WO1999021875A1 (en) 1997-10-24 1999-05-06 University Of Utah Research Foundation Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies
WO1999041372A1 (en) * 1998-02-17 1999-08-19 Astrazeneca Uk Limited Potassium channel polypeptide
US6133275A (en) * 1998-05-06 2000-10-17 Abbott Laboratories 3-phenylpyrrolidine alpha-1 adrenergic compounds
US6794161B1 (en) * 1999-01-26 2004-09-21 Neurosearch A/S Potassium channels and genes encoding these potassium channels
ATE342279T1 (de) * 1999-01-26 2006-11-15 Neurosearch As Kaliumkanäle und für diese kaliumkanäle kodierende gene
IT1312224B1 (it) * 1999-03-23 2002-04-09 Cit Alcatel Circuito pre/post-distorcitore particolarmente per sistemi aradiofrequenza microonde.
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6617131B2 (en) * 2000-03-21 2003-09-09 Aventis Pharma Deutschland Gmbh Nucleic acid molecule encoding the potassium channel protein, KCNQ5
US6767736B2 (en) * 2000-04-03 2004-07-27 Lexicon Genetics Incorporated Human ion channel protein and polynucleotides encoding the same
US6455568B2 (en) * 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
US6376486B1 (en) * 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
AU2001286557A1 (en) * 2000-08-23 2002-03-04 Merck Frosst Canada And Co. Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6613786B2 (en) * 2001-11-02 2003-09-02 Bristol-Myers Squibb Company Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
EP1583821A4 (en) * 2003-01-15 2007-07-18 Millennium Pharm Inc METHODS AND COMPOSITIONS FOR TREATING UROLOGICAL DISORDERS USING GENES 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579
CA2531019A1 (en) * 2003-06-30 2005-01-06 Takeda Pharmaceutical Company Limited Preventive/remedy for urinary disturbance
AU2004272104B2 (en) * 2003-09-10 2011-09-08 Icagen, Inc Fused ring heterocycles as potassium channel modulators
JP2008538784A (ja) * 2005-04-24 2008-11-06 ワイス 膀胱機能を調節するための方法
WO2007084497A1 (en) * 2006-01-19 2007-07-26 Wyeth A novel rat voltage-gated potassium channel

Also Published As

Publication number Publication date
CY1105353T1 (el) 2010-03-03
CN1469739A (zh) 2004-01-21
US20050101004A1 (en) 2005-05-12
NO20031580D0 (no) 2003-04-08
WO2002032419A3 (en) 2002-08-15
JP2004529611A (ja) 2004-09-30
EP1328550A2 (en) 2003-07-23
AR030901A1 (es) 2003-09-03
DK1326597T3 (da) 2006-02-13
DE60116352D1 (de) 2006-02-02
DE60116352T2 (de) 2006-06-22
EP1326597B1 (en) 2005-12-28
ATE314061T1 (de) 2006-01-15
CA2450467C (en) 2011-05-24
US6348486B1 (en) 2002-02-19
WO2002032960A2 (en) 2002-04-25
BR0114718A (pt) 2003-10-14
US7160684B2 (en) 2007-01-09
WO2002032960A3 (en) 2003-04-17
IL155090A0 (en) 2003-10-31
CA2450467A1 (en) 2002-04-25
HUP0303288A2 (hu) 2004-01-28
TWI287984B (en) 2007-10-11
PL360903A1 (en) 2004-09-20
EP1326597A2 (en) 2003-07-16
AU2002211758A1 (en) 2002-04-29
WO2002032419A2 (en) 2002-04-25
JP2004511516A (ja) 2004-04-15
US20060252104A1 (en) 2006-11-09
KR20030040540A (ko) 2003-05-22
AU2002213308A1 (en) 2002-04-29
CN1287781C (zh) 2006-12-06
NO20031580L (no) 2003-06-14
ES2253432T3 (es) 2006-06-01
NZ525301A (en) 2004-10-29
CA2425742A1 (en) 2002-04-25
MXPA03003339A (es) 2003-06-19

Similar Documents

Publication Publication Date Title
HK1056514A1 (en) Use of kcnq potassium channel agonists for the manufacture of a medicament for modulating bladder function
AU4748901A (en) Permanently wettable superabsorbents
MXPA03006753A (es) Tisu absorbente suave.
EP1401367A4 (en) BUFFER APPLICATOR
AU2003210948A8 (en) Multiple-component tampon applicator
AU2002330034A1 (en) Tampon applicator with improved fingergrip
EP1469806A4 (en) BUFFER APPLICATOR
AU2002366326A1 (en) A combination for managing the involuntary loss of bladder control
AU2001265839A1 (en) Use of potassium channel agonists for the treatment of cancer
GB0110817D0 (en) Bandage applicator
AU2001231049A1 (en) Probabilistic use of wireless reserve channels for admission control
AU2001262343A1 (en) Herbicidal agent
GB0112997D0 (en) Irrigator
IL160674A0 (en) Affinity-assay for the human erg potassium channel
AU2001260236A1 (en) Restricted use syringe
AU2001234270A1 (en) Bandage for orthopaedic use
AU2001275696A1 (en) Therapeutic agent
AU2001238185A1 (en) Diaper changing pad
AU2001261552A1 (en) Disposable respirator
AU2002213748A1 (en) Vaginal irrigator
MXPA03006970A (es) Nuevo uso de iloperidona.
AU6286101A (en) New use
AU2001273888A1 (en) New sodium channel (rnav1.5a) and use thereof
AU2002224528A1 (en) New use
IL159925A0 (en) Tampon applicator

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20091016